Tirzepatide 15mg

Within GLP-1-class literature, Tirzepatide is a novel dual agonist targeting both GIP and GLP-1 receptors simultaneously. Phase 3 clinical trials (SURMOUNT) demonstrated average weight loss of 20–22.5% over 72 weeks — greater than any previously approved weight loss drug. It improves insulin sensitivity, cardiovascular markers, and metabolic function through two complementary incretin pathways.

Primary research applications for Tirzepatide include 20–22.5% average weight loss in surmount trials, dual gip + glp-1 receptor mechanism, superior to single glp-1 agents, improved insulin sensitivity and cardiovascular markers. As a Metabolic compound, it is studied in the context of metabolic, weight loss, glp-1 — areas where its mechanism of action has the most direct relevance in preclinical models.

In standard research protocols, Tirzepatide is administered at 2.5–15 mg weekly subcutaneous (dose escalation), with a half-life of ~5 days. This product is supplied by Phiogen as lyophilized powder with independent third-party Certificate of Analysis (COA) documentation confirming 99%+ purity and correct molecular identity on every batch. Tirzepatide 15mg is sold strictly for laboratory and educational use only — it is not FDA-approved for human therapeutic use and is not intended for human consumption, clinical application, or use in animals.